Pharmaceutical impurities: An overview

Indian Journal of Pharmaceutical Education and Research

Volumn 44, Issue 3, 2010, Pages 301-310

  Rama Rao, N ^a   Mani Kiran, S S ^a   Prasanthi, N L ^a  

^a CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Degradation; Efficacy; Formulation; Impurities

Indexed keywords

1,2 DICHLOROETHYLENE; ACETONITRILE; ADRENALIN; AMLODIPINE BESYLATE; BACLOFEN; CHLOROBENZENE; CHLOROFORM; COLECALCIFEROL; CYCLOHEXANE; DICHLOROMETHANE; DICLOFENAC; DIHYDROERGOTAMINE MESILATE; ERGOMETRINE; HYDROCHLOROTHIAZIDE; KANAMYCIN; KETOROLAC; NALIDIXIC ACID; NIFEDIPINE; NITROPRUSSIDE SODIUM; OFLOXACIN; PARACETAMOL; PENICILLIN G; PENICILLIN G POTASSIUM; PHENOTHIAZINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBOFLAVIN; TETRACYCLINE; THIOMERSAL; TRYPTOPHAN; UNINDEXED DRUG;

DECARBOXYLATION; DRUG COATING; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPURITY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; DRUG STORAGE; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMIDITY; HYDROLYSIS; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; MEDICAL LITERATURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION; PACKAGING MATERIAL; PHOTOLYSIS; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; TANDEM MASS SPECTROMETRY; TEMPERATURE; ULTRAVIOLET RADIATION;

EID: 77957369099     PISSN: 00195464     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Ahuja Satinder. Impurities Evaluation of Pharmaceuticals. New York: Marcel Dekker; 1998.
2. International Conferences on Harmonization, Draft revised Guidance on Impurities in new drug Substances. Q3A®. Federal Register. 2000; 65(140):45085-45090.
3. International Conferences on Harmonization, Draft revised Guidance on Impurities in new drug Products. Q3B®. Federal Register. 2000; 65(139):44791-44797.
4. International Conferences on Harmonization, Impurities-Guidelines for residual solvents. Q3C. Federal Register. 1997; 62(247): 673-77.
5. ICH Topic Q3A; Impurities testing Guideline: Impurities in New drug substances, The European Agency for the Evaluation of Medicinal products Human medicines evaluation unit. 1995.
6. International Conferences on Harmonization Specifications. Q6A: Test procedures and Acceptance Criteria for New drug substances and New drug products. Chemical substances. 1999; 65(146): 67488.
7. Alsante KM, Hatajik TD, Lohr LL, and Sharp TR. Isolation and identification of process related impurities and degradation products from pharmaceutical drug candidates. Part 1. Amer. Pharm. Review. 2001; 4(1): 70-78.
8. Lohr LL, Sharp TR, Alsante KM and Hatajik TD. Isolation and identification of process related impurities and degradation products form pharmaceutical drug candidates. Part II: The roles of NMR and Mass Spectroscopy. American Pharmaceutical Review., 2001.
9. Gorog. Sandor, Chemical and analyt ical characterization of related organic impurities in drugs. Anal. Bioanal.Chem, 2003; 377: 852 - 862.
10. Sanjay B. Bari, Bharati R. Kadam, Yogini S. Jaiswal, et al. Impurity profile: Significance in Active Pharmaceutical Ingredient. Eurasian J. Anal. Chem, 2007; 2(1): 32-53.
11. Jiben roy, Pharmaceutical Impurities - A mini Review. AAPS Pharm. sci tech, 2002; 3(2): 1-9.
12. Janko Zmitek et.al. Sources of impurities - investigation of 4 - (2 - chlorophenyl) - (3 - ethoxy carbonyl - 5 - methoxy carbonyl - 6 - methyl - 2 -[(2 - phthalimidoethoxy)methyl] - 1,4 - dihydropyridine traces formation during the synthesis of amlodipine besylate. Acta. Chim. Slov.2000; 47: 63 - 68.
13. Ahuja Satinder., Handbook of Modern Pharmaceutical analysis. Academic press, 2001; 298.
14. Poonam Kushwaha. The organic impurities in pharmaceuticals. Pharma info. net., 2008, vol.6(4).
15. Ahuja S. isolation and characterization of pharmaceutical impurities evaluation. New York; Marcel Dekker. 2000.
16. Connor KA, Amidon GL, Stella VJ. Chemical stability of pharmaceuticals - A handbook for pharmacists. New York: John Wiley & Sons; 1986.
17. Koji U. Atsuya H, kazuichi U, Masayuki G. Matrix media selection for the determination of residual solvents in pharmaceutical by static head space chromatography, J. Chrom. A. 2004; 1057: 203 - 210.
18. Anil M. Dwivedi. Residual solvent analysis in pharmaceuticals. Int. J. Pharma. Excip, 2003; April - june: 33 - 37.
19. Food and drug administration for immediate release consumer media: 888- Info- FDA. May 6, 1998.
20. Roy J, Islam M, Khan AH, Das SC, Akhteruzzaman M, Deb AK, Alam AH M. Diclofenac sodium injection sterilized by autoclave and the occurrence of cyclic reaction producing a small amount of impurity. J. Pharm. Sci. 2001; (90): 541- 544.
21. Buhler V. Vademecum for Vitamin Formulation. Stuttgart, Germany: Wiss. Verl- Ges; 1988.
22. Roy J, Bhuiyan K. et al., Injectable ergometrine: Stability and packaging for developing countries. Indian Drugs. 1997; 34(11):634-636.
23. Roy J, Mahmud M, Sobhan A, et al., Marketed vitamin B-complex injectables: stability and mutual interaction. Drug Dev. And Ind Pharm. 1994; 20(13): 2157- 2163.
24. Walker GJA, Hogerzeil HV, Hillgreen U. Potency of ergometrine in tropical countries. Lancet. 1988; 2:393.
25. Smith A, Pennefather P M, Kaye S B and Hart C A., Fluroquinolones -place in ocular therapy. Indian drugs., 2001, 61(6): 747.
26. Tobin C. Sunlight, eyes and light-sensitive antibiotics, South mead Hospital Bristol, University of Bristol.
27. European pharmacopoeia, Directorate for the quality of medicines of the council of Europe, Strasbourg, France: 2002.
28. Roy J, Das SC. The effect of sunlight on Ciprofloxacin eye drops. In press.
29. Alsante K M, Boutres P, Harwood JW et al., Pharmaceutical impurity identification: A case study using a Multi disciplinary Approach. Jour. Pharm. Sci. 2004; 93 (9): 2296.
30. Qiu. F and Norwood, D.L., Identification of pharmaceuticals, Journal of liquid chromatography and related technologies. 2007; 30: 877 - 935.
31. Winger BE, Kemp CAJ. Characterization of pharmaceutical compounds and related substances by using HPLC FTICR-MS and tandem mass spectrometry. Americ. Pharm. Rev. Summer issue 2001.
32. Volk K J, Hill S E. Kerns E H, Lee M S. profiling degradent of paclitaxel using liquid chromatography-mass spectrometry and liquid chromatography- tandem mass spectrometry sub structural techniques. J Chromatogr B. 1997; 696(1): 99.
33. Puranik S.B. Organic volatile impurities in Pharmaceuticals. 2007; 352 - 359.